Welcome
Support Centre
16 April 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
Psychological Prevention of Relapse in Psychosis
ISRCTN ISRCTN83557988
DOI 10.1186/ISRCTN83557988
ClinicalTrials.gov identifier
EudraCT number
Public title Psychological Prevention of Relapse in Psychosis
Scientific title A randomised controlled trial of cognitive behavioural therapy and family intervention for the prevention of relapse and reduction of symptoms in psychosis
Acronym PRP
Serial number at source 062452
Study hypothesis The trial is designed to answer questions both about outcome and about mechanisms of treatment change of Cognitive Behaviour Therapy (CBT) and Family Intervention (FI) for psychosis. The trial consists of two pathways (for those with carers and those without) incorporating randomisation within each pathway, after stratification by treatment centre and whether the participant is an inpatient at the time of recruitment.

Trial I has two conditions: CBT and Treatment As Usual (TAU).
Trial II has three conditions: CBT, FI and TAU.

Primary Outcome hypotheses:
1. In Trial Pathway I, CBT will reduce rates of relapse and total days in hospital in the two year follow up compared to TAU, and that CBT will be cost neutral.
2. In Trial Pathway II, Both CBT and FI will reduce relapse and days in hospital at two year follow up compared with TAU, and that CBT and FI will be cost neutral.

Secondary outcome hypotheses:
1. CBT and FI will both reduce relapse and psychotic and emotional symptoms at 12 months (end of treatment) compared with TAU. The main change in psychotic symptoms will be in delusions and hallucinations.
2. FI, but not CBT, will increase social functioning compared to TAU at 24 months.
3. CBT, but not FI, will reduce psychotic and emotional symptoms at 24 months compared with TAU.
Lay summary Not provided at time of registration
Ethics approval Added 03/03/2009: South East Multi-Centre Research Ethics Committee gave approval on the 4th June 2001 (ref: MREC01/1/24). All local research ethics committees also subsequently approved the study.
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Psychosis
Participants - inclusion criteria Participants are recruited from identified psychiatric teams in four NHS Trusts.

Entry criteria:
1. Current diagnosis of psychosis
2. Non-affective (International Statistical Classification of Diseases and Related Health Problems, Tenth edition [ICD-10], F20)
3. Aged 18 to 65 years, either sex
4. Second or subsequent episode, which started not more than three months before entry
5. Rated at least four (moderate severity) on the Positive and Negative Syndrome Scale (PANSS) on at least one positive psychotic symptom
Participants - exclusion criteria Added 03/03/2009:
1. Primary diagnosis of alcohol or substance dependency, organic syndrome or learning disability
2. Inadequate command of English to engage in psychological therapy
3. Unstable residential arrangements and so unlikely to be available for therapy and/or assessments over period of trial
Anticipated start date 01/12/2001
Anticipated end date 31/10/2006
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 301
Interventions For participants with carers:
1. Cognitive behavioural therapy (CBT) and treatment as usual (TAU)
2. Family intervention (FI) and TAU
3. TAU only

For participants with no carers:
1. CBT and TAU
2. TAU only
Primary outcome measure(s) Relapse and days in hospital over 24 months.
Secondary outcome measure(s) 1. Pattern of symptom change (PANSS total scores and subscale scores, Psychotic SYmptom RATing Scales [PSYRATS], Beck Depression Inventory [BDI], Beck Anxiety Inventory [BAI]) over 12 and 24 months
2. Social functioning (time budget) at 24 months
Sources of funding The Wellcome Trust (UK) (grant ref: 062452)
Trial website
Publications 1. 2006 results in http://www.ncbi.nlm.nih.gov/pubmed/16889588
2. 2008 results in http://www.ncbi.nlm.nih.gov/pubmed/18515890
3. 2012 results in http://www.ncbi.nlm.nih.gov/pubmed/22499781
4. 2012 subgroup analysis results in http://www.ncbi.nlm.nih.gov/pubmed/21939591
5. 2013 results in http://www.ncbi.nlm.nih.gov/pubmed/22499781
Contact name Prof  Philippa  Garety
  Address Department of Psychology
PO Box 77
Institute of Psychiatry
Denmark Hill
  City/town London
  Zip/Postcode SE5 8AF
  Country United Kingdom
  Tel +44 (0)20 7848 0197
  Fax +44 (0)20 7848 5006
  Email P.Garety@iop.kcl.ac.uk
Sponsor King's College London (UK)
  Address Institute of Psychiatry
De Crespigny Park
  City/town London
  Zip/Postcode SE5 8AF
  Country United Kingdom
  Tel +44 (0)20 7848 0675
  Fax +44 (0)20 7848 0147
  Email g.dale@iop.kcl.ac.uk
  Sponsor website: http://www.iop.kcl.ac.uk
Date applied 25/06/2003
Last edited 19/04/2013
Date ISRCTN assigned 25/06/2003
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.